Khan A, Lin P, Kamdar N, Peterson M, Mahmoudi E. Potentially preventable hospitalizations and use of preventive services among people with multiple sclerosis: large cohort study, USA. Mult Scler Relat Disord. 2022 Dec;68:104105. doi: 10.1016/j.msard.2022.104105
Kamudoni P, Amtmann D, Johns J, Cook KF, Salem R, Salek S, Raab J, Middleton R, Repovic P, Alschuler KN, von Geldern G, Wundes A, Barrett A, Olayinka-Amao B, Henke C. The validity, responsiveness, and score interpretation of the PROMISnq Physical Function - Multiple Sclerosis 15a short form in multiple sclerosis. Mult Scler Relat Disord. 2022 Jun;62:103753. doi: 10.1016/j.msard.2022.103753
Poudel N, Banjara B, Kamau S, Frost N, Ngorsuraches S. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2021 Feb;48:102720. doi: 10.1016/j.msard.2020.102720
Penner I-K, McDougall F, Brown TM, Slota C, Doward L, Julian L, Belachew S, Miller D. Exploring the impact of fatigue in progressive multiple sclerosis: a mixed-methods analysis. Mult Scler Relat Disord. 2020 Aug;43:102207. doi: 10.1016/j.msard.2020.102207
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Groenwold RH, Klungel OH, Altman DJ, van der Graaf Y, Hoes AW, Moons KG, Rivero E, Fortuny J, PROTECT WP2. Adjustment for continuous confounders: an example of how to prevent residual confounding. Can Med Assoc J. 2013 Mar 19;185(5):401-6. doi: 10.1503/cmaj.120592
Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. Can Med Assoc J. 2011 Apr 1;183(7):E411-9.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Strickland A, Brogan AJ, Krauss J, Martindale R, Cresci G. Is the use of specialized nutritional formulations a cost-effective strategy? A national database evaluation. J Parenter Enter Nutr. 2005 Jan 1;29(1 Suppl):S81-91.